Bloomberg Technology

23andMe CEO on Trading Debut, GSK Deal, Branson SPAC

Jun.17 — 23andMe Inc. CEO Anne Wojcicki discusses the DNA-testing company’s NASDAQ trading debut, a collaboration on drug development with GlaxoSmithKline Plc, and the choice to go public through a merger with VG Acquisition Corp., a special-purpose acquisition company founded by billionaire Richard Branson. She speaks with Bloomberg’s Emily Chang on “Bloomberg Markets: The Close.”

Published

on

Jun.17 — 23andMe Inc. CEO Anne Wojcicki discusses the DNA-testing company’s NASDAQ trading debut, a collaboration on drug development with GlaxoSmithKline Plc, and the choice to go public through a merger with VG Acquisition Corp., a special-purpose acquisition company founded by billionaire Richard Branson. She speaks with Bloomberg’s Emily Chang on “Bloomberg Markets: The Close.”

2 Comments

  1. Aperture Online

    June 17, 2021 at 8:52 pm

    So does that mean that I can destroy my DNA with drugs so that I’m older to go public faster?

  2. mrPmj00

    June 17, 2021 at 11:44 pm

    __…Stocks for the next 5 years: Amazon, Apple, Facebook, Microsoft, Netflix. Disney, Wells Fargo, Lowes for the
    recovery.
    My family and friends use things from these companies every day so I know that these companies will continue to do well.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version